yuko kanbayashi

About yuko kanbayashi

yuko kanbayashi, With an exceptional h-index of 12 and a recent h-index of 9 (since 2020), a distinguished researcher at Kyoto Prefectural University of Medicine, specializes in the field of supportive care, oncology, palliative care.

His recent articles reflect a diverse array of research interests and contributions to the field:

Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients

Predictors for the development of thromboembolic events in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis

Factors related to oral mucositis or dysgeusia in breast cancer patients undergoing fluorouracil, epirubicin, and cyclophosphamide therapy: A single-center, retrospective study

Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance

Evaluation of cardiac adverse events with ponatinib using a spontaneous reporting database

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan

Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study

Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database

yuko kanbayashi Information

University

Position

___

Citations(all)

500

Citations(since 2020)

273

Cited By

322

hIndex(all)

12

hIndex(since 2020)

9

i10Index(all)

18

i10Index(since 2020)

8

Email

University Profile Page

Kyoto Prefectural University of Medicine

Google Scholar

View Google Scholar Profile

yuko kanbayashi Skills & Research Interests

supportive care

oncology

palliative care

Top articles of yuko kanbayashi

Title

Journal

Author(s)

Publication Date

Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients

DARU Journal of Pharmaceutical Sciences

Yuko Kanbayashi

Eren Tsuchiya

Tadashi Shimizu

Mayako Uchida

2024/4/26

Predictors for the development of thromboembolic events in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis

Oncology

Yuko Kanbayashi

Takeshi Ishikawa

Eigo Otsuji

Koichi Takayama

2023/9/27

Factors related to oral mucositis or dysgeusia in breast cancer patients undergoing fluorouracil, epirubicin, and cyclophosphamide therapy: A single-center, retrospective study

Yuko Kanbayashi

Tetsuya Taguchi

Takeshi Ishikawa

Koichi Takayama

2024/2/21

Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance

Oncology

Yuko Kanbayashi

Momoko Kobayashi

Miku Anzai

Tadashi Shimizu

Mayako Uchida

2023/12/12

Evaluation of cardiac adverse events with ponatinib using a spontaneous reporting database

Oncology

Yuko Kanbayashi

Mayako Uchida

Kana Nakano

Haruka Wakabayashi

Tadashi Shimizu

2023/7/3

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan

Scientific Reports

Yuko Kanbayashi

Tadashi Shimizu

Asuka Kojima

Miku Anzai

Rika Kawai

...

2023/5/31

Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study

Oncology

Yuko Kanbayashi

Tetsuya Taguchi

Takeshi Ishikawa

Eigo Otsuji

Koichi Takayama

2023/4/19

Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database

Medical Oncology

Yuko Kanbayashi

Mayako Uchida

Misui Kashiwagi

Hitomi Akiba

Tadashi Shimizu

2022/9/29

Evaluation of cardiac toxicity with ponatinib using a spontaneous reporting database

Yuko Kanbayashi

Mayako Uchida

Kana Nakano

Haruka Wakabayashi

Tadashi Shimizu

2022/6/29

Predictors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study

Yuko Kanbayashi

Tetsuya Taguchi

Takeshi Ishikawa

Koichi Takayama

2022/5/9

Predictors for development of oxaliplatin-induced peripheral neuropathy in cancer patients as determined by ordered logistic regression analysis

Plos one

Yuko Kanbayashi

Takeshi Ishikawa

Yoshiaki Kuriu

Eigo Otsuji

Koichi Takayama

2022/9/29

Predictors for Effectiveness of Naldemedine in Patients with Cancer Pain: A Retrospective, Single-Institution Analysis

YUKO KANBAYASHI

Mayumi Shimizu

Yuichi Ishizuka

Shohei Sawa

Katsushige Yabe

...

2022/1/18

Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database

Scientific Reports

Yuko Kanbayashi

Mayako Uchida

Misui Kashiwagi

Hitomi Akiba

Tadashi Shimizu

2022/9/16

Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: Post hoc analysis of a prospective, phase II, self-controlled clinical …

Medical Oncology

Yuko Kanbayashi

Koichi Sakaguchi

Takeshi Ishikawa

Yusuke Tabuchi

Ryo Takagi

...

2022/7/19

Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis

Supportive Care in Cancer

Yuko Kanbayashi

Yuichi Ishizuka

Mayumi Shimizu

Shohei Sawa

Katsushige Yabe

...

2022/7

Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis

Plos one

Yuko Kanbayashi

Mayumi Shimizu

Yuichi Ishizuka

Shohei Sawa

Katsushige Yabe

...

2022/12/9

Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis

Scientific Reports

Yuko Kanbayashi

Koichi Sakaguchi

Takeshi Ishikawa

Koichi Takayama

Tetsuya Taguchi

2021/10/8

Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis

Scientific Reports

Yuko Kanbayashi

Koichi Sakaguchi

Fumiya Hongo

Takeshi Ishikawa

Yusuke Tabuchi

...

2021/1/13

Predictors of the usefulness of mirogabalin for neuropathic pain: a single-institution retrospective study

Die Pharmazie-An International Journal of Pharmaceutical Sciences

Y Kanbayashi

F Amaya

K Ikoma

H Ueno

Y Tabuchi

...

2020/11/1

Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis

Scientific Reports

Yuko Kanbayashi

Takeshi Ishikawa

Yusuke Tabuchi

Koichi Sakaguchi

Yoshimi Ouchi

...

2020/2/6

See List of Professors in yuko kanbayashi University(Kyoto Prefectural University of Medicine)